|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Allum WH, Stenning SP, Bancewicz J, Clark
PI and Langley RE: Long-term results of a randomized trial of
surgery with or without preoperative chemotherapy in esophageal
cancer. J Clin Oncol. 27:5062–5067. 2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Paccez JD, Vogelsang M, Parker MI and
Zerbini LF: The receptor tyrosine kinase Axl in cancer: Biological
functions and therapeutic implications. Int J Cancer.
134:1024–1033. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Qu X, Liu G, Zhong X, Li X and Zhang Q:
Role of AXL expression in non-small cell lung cancer. Oncol Lett.
12:5085–5091. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Graham DK, DeRyckere D, Davies KD and Earp
HS: The TAM family: Phosphatidylserine sensing receptor tyrosine
kinases gone awry in cancer. Nat Rev Cancer. 14:769–785.
2014.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Zhang Z, Lee JC, Lin L, Olivas V, Au V,
LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al:
Activation of the AXL kinase causes resistance to EGFR-targeted
therapy in lung cancer. Nat Genet. 44:852–860. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Duan Y, Hu B, Qiao C, Luo L, Li X, Wang J,
Liu H, Zhou T, Shen B, Lv M and Feng J: Engineered AXL-ECD-Fc
variants that abolish the AXL/Gas6 interaction suppress tumor cell
migration. Oncol Lett. 17:5784–5792. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hsieh MS, Yang PW, Wong LF and Lee JM: The
AXL receptor tyrosine kinase is associated with adverse prognosis
and distant metastasis in esophageal squamous cell carcinoma.
Oncotarget. 7:36956–36970. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Paccez JD, Duncan K, Vava A, Correa RG,
Libermann TA, Parker MI and Zerbini LF: Inactivation of GSK3β and
activation of NF-κB pathway via Axl represents an important
mediator of tumorigenesis in esophageal squamous cell carcinoma.
Mol Biol Cell. 26:821–831. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Elkabets M, Pazarentzos E, Juric D, Sheng
Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, et
al: AXL mediates resistance to PI3Kα inhibition by activating the
EGFR/PKC/mTOR Axis in head and neck and esophageal squamous cell
carcinomas. Cancer Cell. 27:533–546. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhang G, Kong X, Wang M, et al: AXL is a
marker for epithelial-mesenchymal transition in esophageal squamous
cell carcinoma. Oncol Lett. 15:1900–1906. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Myers SH, Brunton VG and Unciti-Broceta A:
AXL inhibitors in cancer: A medicinal chemistry perspective. J Med
Chem. 59:3593–3608. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wu Y, Hu L, Liang Y, Li J, Wang K, Chen X,
Meng H, Guan X, Yang K and Bai Y: Up-regulation of lncRNA CASC9
promotes esophageal squamous cell carcinoma growth by negatively
regulating PDCD4 expression through EZH2. Mol Cancer.
16(150)2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Holland SJ, Pan A, Franci C, Hu Y, Chang
B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, et al: R428, a
selective small molecule inhibitor of Axl kinase, blocks tumor
spread and prolongs survival in models of metastatic breast cancer.
Cancer Res. 70:1544–1554. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yang PW, Liu YC, Chang YH, Lin CC, Huang
PM, Hua KT, Lee JM and Hsieh MS: Cabozantinib (XL184) and R428
(BGB324) inhibit the growth of esophageal squamous cell carcinoma
(ESCC). Front Oncol. 9(1138)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Meyer AS, Miller MA, Gertler FB and
Lauffenburger DA: The receptor AXL diversifies EGFR signaling and
limits the response to EGFR-targeted inhibitors in Triple-negative
breast cancer cells. Sci Signal. 6(ra66)2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hansen MB, Nielsen SE and Berg K:
Re-examination and further development of a precise and rapid dye
method for measuring cell growth/cell kill. J Immunol Methods.
119:203–210. 1989.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kong LL, Man DM, Wang T, Zhang GA and Cui
W: siRNA targeting RBP2 inhibits expression, proliferation,
tumorigenicity and invasion in thyroid carcinoma cells. Oncol Lett.
10:3393–3398. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tang Z, Yang L, Wang Y, Xue R, Zhang J,
Huang W, Chen PC and Sung KL: Contributions of different
intraarticular tissues to the acute phase elevation of synovial
fluid MMP-2 following rat ACL rupture. J Orthop Res. 27:243–248.
2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Antony J and Huang RY: AXL-Driven EMT
state as a targetable conduit in cancer. Cancer Res. 77:3725–3732.
2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang G, Wang M, Zhao H and Cui W:
Function of Axl receptor tyrosine kinase in non-small cell lung
cancer. Oncol Lett. 15:2726–2734. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tai KY, Shieh YS, Lee CS, Shiah SG and Wu
CW: Axl promotes cell invasion by inducing MMP-9 activity through
activation of NF-kappaB and Brg-1. Oncogene. 27:4044–4055.
2008.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Reichl P, Dengler M, van Zijl F, Huber H,
Führlinger G, Reichel C, Sieghart W, Peck-Radosavljevic M,
Grubinger M and Mikulits W: Axl activates autocrine transforming
growth factor-β signaling in hepatocellular carcinoma. Hepatology.
61:930–941. 2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chiu KC, Lee CH, Liu SY, Yeh CT, Huang RY,
Yuh DY, Cheng JC, Chou YT and Shieh YS: Protumoral effect of
macrophage through Axl activation on mucoepidermoid carcinoma. J
Oral Pathol Med. 43:538–544. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Han J, Tian R, Yong B, Luo C, Tan P, Shen
J and Peng T: Gas6/Axl mediates tumor cell apoptosis, migration and
invasion and predicts the clinical outcome of osteosarcoma
patients. Biochem Biophys Res Commun. 435:493–500. 2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wu G, Ma Z, Hu W, Wang D, Gong B, Fan C,
Jiang S, Li T, Gao J and Yang Y: Molecular insights of Gas6/TAM in
cancer development and therapy. Cell Death Dis.
8(e2700)2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Linger RM, Keating AK, Earp HS and Graham
DK: TAM receptor tyrosine kinases: Biologic functions, signaling,
and potential therapeutic targeting in human cancer. Adv Cancer
Res. 100:35–83. 2008.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhang G, Wang M, Zhao H and Cui W:
Function of Axl receptor tyrosine kinase in non-small cell lung
cancer. Oncol Lett. 15:2726–2734. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Verma A, Warner SL, Vankayalapati H,
Bearss DJ and Sharma S: Targeting Axl and Mer kinases in cancer.
Mol Cancer Ther. 10:1763–1773. 2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Scaltriti M, Elkabets M and Baselga J:
Molecular pathways: AXL, a membrane receptor mediator of resistance
to therapy. Clin Cancer Res. 22:1313–1317. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000.PubMed/NCBI View Article : Google Scholar
|
